$OMDA

Duffy Sean P. sold $587K of OMDA

Duffy Sean P. (Chief Executive Officer) sold 25,886 shares of Omada Health, Inc. (OMDA) at an average of $22.68 ($22.67–$22.70, $0.59M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Duffy Sean P.
Published Jul 6, 2026, 9:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$OMDA
Neutral
high confidence
Mentioned
$OMDA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMDANeutralLow
01

Why it matters

The disclosure updates the insider trading record but does not introduce new fundamentals (no earnings, guidance, deal, or regulatory action).

02

Market read

Traders may note the insider sale for sentiment/positioning, but the 10b5-1 structure reduces the likelihood of a durable price signal.

03

What to watch

The article provides only the sale details; it does not state motivations, tax planning context, or whether other insiders are buying/selling around the same window.

Relevance 4/10Novelty 3/10Timing: Filed after-hours on 2026-07-06; reflects 2026-07-01 sale execution.

Background

This is an SEC Form 4 disclosure of an insider open-market sale by Omada Health CEO Sean P. Duffy under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$OMDANeutralHigh confidence
Context

CEO Sean P. Duffy sold 25,886 shares of Omada Health on a 10b5-1 plan at about $22.685/share, totaling ~$587K.

Expected impact

Low near-term impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan and no accompanying operational or guidance change.

Market effects

No clear sector read-through; this is company-specific insider trading with no stated business catalyst.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with management de-risking ahead of volatility, so some traders may still fade strength.

Key entities

  • Omada Health, Inc.

    Subject of the Form 4 insider sale disclosure; CEO Sean P. Duffy sold shares under a 10b5-1 plan.

  • Sean P. Duffy

    CEO and officer/director who executed the open-market sale(s).

Related articles

$OMDAHigh

Omada Health, Inc. (OMDA): Results of Operations and Financial Condition

Omada Health, Inc. (OMDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 q2fy26pressrelease.htm EX-99 Document Omada Health Reports Second Quarter 2026 Results and Announces CEO Transition • Revenue Grew 43% and Total Members Increased 45% Year over Year, with Gross Margin Reaching a New Quarterly Record • Company Announces Sean Duffy to Becom